timothy sykes logo
SPRC Stock Jumps As SciSparc Advances Tourette Trial And AI Pivot Thumbnail
G Google News

SPRC Stock Jumps As SciSparc Advances Tourette Trial And AI Pivot

TIM SYKES•UPDATED OCT. 26, 2026, 7:48 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

SciSparc Ltd. stocks have been trading up by 39.44 percent following highly positive sentiment from its latest news coverage.

Key Takeaways

  • NeuroThera Labs, majority-owned by SPRC, cleared manufacturing and European QP batch release for Tourette candidate SCI-110, unlocking shipment of clinical supplies and Phase IIb trial enrollment at three international sites.
  • CliniQuantum, another NeuroThera unit, benchmarked a GPU-accelerated quantum-simulation workflow that ran ~16.8x faster than CPU-only setups when scanning billions of three-gene combinations on a major cloud quantum architecture.
  • The parent company plans a strategic pivot into Agentic AI, targeting cybersecurity and fintech, backed by a new Scientific Advisory Board for AI and cybersecurity and active scouting across the Agentic AI ecosystem.

Candlestick Chart

Live Update At 07:47:57 EDT: On Monday, October 26, 2026 SciSparc Ltd. stock [NASDAQ: SPRC] is trending up by 39.44%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SPRC has been trading like a classic small-cap biotech rollercoaster. In early October 2026, SciSparc Ltd. closed near $4.70. By 2026/10/23, SPRC finished at $1.09. That is a steep drawdown, signaling traders have aggressively repriced the story despite recent catalysts.

The daily chart shows a sharp gap-and-fade on 2026/10/15, with SPRC spiking to $5.33 and then closing at $2.00 the same day. Since then, the stock has bled lower in a series of lower highs and lower lows, a textbook downtrend. Recent intraday action between roughly $1.40 and $1.60 shows tighter ranges and heavy churn, which often signals a battle between shorts locking in gains and dip buyers fishing for a bounce.

More Breaking News

Fundamentally, SciSparc is still very early-stage. Revenue sits around $0.86M, and at current prices SPRC trades near 3.0x sales. Book value per share is roughly $7.30, while the stock trades near a fraction of that, reflecting both deep skepticism and potential value if any pipeline or AI initiative gains traction. The balance sheet lists about $4.59M in cash against relatively modest liabilities, which gives SciSparc Ltd. some runway — but not unlimited time — to execute.

Why Traders Are Watching SPRC Now

Traders are locked in on SPRC because multiple high-risk, high-reward narratives are colliding at once.

First, the near-term biotech catalyst. NeuroThera Labs, the majority-owned SciSparc subsidiary, has moved its Tourette drug candidate SCI-110 into a more serious stage. Manufacturing is done. European Qualified Person batch release is in hand. That clears the way for shipping trial material and enrolling patients in an FDA-approved Phase IIb trial across three international sites. For biotech traders, this is a classic de-risking step: the project is no longer just a plan on paper, it is in the clinic with real patients.

Data is still down the road, and SPRC will trade on headlines, rumors, and speculation in the meantime. Any update on enrollment pace or safety could trigger sharp moves in either direction. This is exactly the kind of setup day traders in the Sykes community look for — strong catalysts but uncertain outcomes, paired with a thin float and a beaten-down chart.

Second, SciSparc’s AI angle gives SPRC a second story line. CliniQuantum’s ~16.8x speedup on a GPU-accelerated quantum-simulation platform shows that the SciSparc ecosystem is not just talking about AI and quantum; it is actually running heavy workloads on an S&P 500 company’s cloud quantum architecture. That performance win does not yet equal revenue or clinical validation, but it plants SPRC inside two of Wall Street’s favorite themes: AI and quantum.

Layer on top SciSparc Ltd.’s announced pivot toward Agentic AI in cybersecurity and financial technology, backed by a new AI and cybersecurity Scientific Advisory Board. Now traders see a biotech/tech hybrid narrative. That mix can fuel violent momentum runs when headlines line up — and equally brutal dumps when sentiment turns.

Conclusion

For active traders, SPRC is a classic story-stock around a dollar: real catalysts, real risk, and wild volatility. On one side, SciSparc Ltd. has a live, FDA-approved Phase IIb trial for SCI-110 in Tourette syndrome gearing up across three international sites through NeuroThera Labs. That is a tangible path to value creation if later data cooperates. On another side, CliniQuantum is showcasing serious compute power in quantum-simulation work, while the broader company leans into Agentic AI plays in cybersecurity and fintech with its new Scientific Advisory Board.

None of this guarantees future cash flows, and the market knows it. That is why SPRC trades well below stated book value despite the AI and biotech narratives. The chart is your lie detector here. Downtrending prices tell you big money is still skeptical, even as news flow turns more bullish. For short-term trading, that tension — good headlines versus weak price action — often sets up sharp squeezes when shorts crowd in too deep, or breakdowns when hope runs out.

The key is discipline. As Tim Sykes likes to remind traders, “Cut losses quickly, or the market will do it for you, with interest.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. With SPRC, that means respecting your risk, trading the price action around catalysts, and remembering this is educational and research content — not trading advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”